跳至主要内容
临床试验/NCT05207774
NCT05207774进行中(未招募)不适用

Pre-operative Intranasal Oxytocin for Enhancing Bariatric-induced Diabetes remissionPre-operative Intranasal Oxytocin for Enhancing Bariatric-induced Diabetes Remission

Soroka University Medical Center1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2020年1月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
3
试验地点
1
主要终点
Number of participants with diabetes remission 1 year post surgery

研究概览

简要总结

This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in obese adults with diabetes undergoing bariatric surgery. Subjects will be randomized to receive of intranasal oxytocin or placebo (8 units 3 times daily) for 8 weeks prior surgery. Study visits include screening to determine eligibility, CGM will be connected before and after oxytocin administration, and 1 year post surgery. blood tests including oral glucose tolerance test will be done and fat samples will be taken during surgery. The investigator's hypothesis is that oxytocin administration prior bariatric surgery can induce diabetes remission in patients with diabetes

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-65
  • Diabetes Mellitus type 2
  • HBA1C < or= 9
  • eligible for bariatric surgery (after a hospital bariatric committee)
  • Advanced diarem>6
  • Signed an informed consent -

排除标准

  • HBA1C above 9
  • Prior bariatric surgery in the past 6 years
  • secondary diabetes
  • steroid therapy
  • uncontrolled hypertension(>180/100)
  • Arythmia: paroxysmal tachyarythmia or high degree AV-Block

研究组 & 干预措施

oxytocin

Experimental

8 U/oxytocin three-times daily, 30 min before breakfast, lunch and dinner, using a nasal atomizer for 8 weeks

干预措施: Oxytocin (Drug)

placebo

Placebo Comparator

intranasal spray containing placebo three-times daily, 30 min before breakfast, lunch and dinner, using a nasal atomizer for 8 weeks

干预措施: placebo (Drug)

结局指标

主要结局

Number of participants with diabetes remission 1 year post surgery

时间窗: 1 year post surgery

HBA1C less then 6.5% without need for diabetes medication

Number of participants who improved their glycemic control

时间窗: 8 weeks

increase in "Time in Range" by 10% and or decrease in HBA1C by 1 % 8 weeks from treatment

weight loss

时间窗: 1 year

weight reduction - kg.

obesity

时间窗: 1 year

change in waist circumference

次要结局

  • lipids-NON HDL CHOLESTEROL(1 year)
  • lipids-HDL CHOLESTEROL(1 year)
  • Rate of Insulin secretion(1 year)
  • Rate of insulin resistance(1 year)
  • lipids-LDL CHOLESTEROL(1 year)
  • lipids-Triglycerides(1 year)
  • blood pressure(1 year)
  • urine microalbumin(1 year)
  • HPA axis(1 year)
  • systemic inflammation(1 year)
  • omental and subcutaneous fat inflammation(8 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验